Validation of OraQuick HCV Rapid Antibody Test in Postmortem Specimens

Area of Science:

• Forensic Toxicology
• Infectious Disease Diagnostics
• Public Health

Background:

• Hepatitis C virus (HCV) infection diagnosis relies on laboratory-based assays.
• The OraQuick HCV Rapid Antibody Test is a widely used diagnostic tool, but its performance in postmortem samples is not well-established.
• Postmortem blood presents unique challenges for diagnostic testing due to potential sample degradation and viscosity changes.

Purpose of the Study:

• To evaluate the diagnostic performance of the OraQuick HCV Rapid Antibody Test using postmortem blood samples.
• To compare the OraQuick test results against a gold-standard laboratory-based serum immunoassay (SI).
• To determine the reliability of the OraQuick test for diagnosing HCV infection in a postmortem setting.

Main Methods:

• Blood samples were collected from 51 decedents investigated by Medical Examiner's Offices.
• Each sample was tested using both the OraQuick HCV Rapid Antibody Test and a laboratory-based SI.
• Results from the two testing methods were compared to assess accuracy.

Main Results:

• The OraQuick HCV Rapid Antibody Test demonstrated a sensitivity of 95.65% and a specificity of 96.15% when compared to the gold-standard SI.
• These results indicate a high level of agreement between the rapid test and the laboratory assay in postmortem blood.

Conclusions:

• The OraQuick HCV Rapid Antibody Test is a reliable method for diagnosing hepatitis C infection in postmortem blood.
• The test is effective even with a postmortem sample acquisition time of less than 21.5 hours.
• The OraQuick test may offer advantages over traditional laboratory-based assays due to potential challenges with postmortem blood viscosity.